Biotech entity
Every one of those 1 sits in a single category, pharma. TCE is most often covered alongside ATG-201, which appears in 1 of these 1 story. Each story carries 3 original sources on average, compared with 2.8 for the broader beat in this window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. TCE is most often covered alongside ATG-201, which appears in 1 of these 1 story. Each story carries 3 original sources on average, compared with 2.8 for the broader beat in this window. Their average consequence score of 6 runs below the beat's 6.4 for that window. We currently track 1 Biotech story that mention TCE, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TCE. Shared-story counts are live from our verified record — not editorial picks.
Profitability Target
Antengene aims to achieve its first full year of profitability.
AACR 2026
Antengene scheduled to present data on next-generation ADCs and TCEs.
2025 FY Results
Company announces full-year results and confirms shift toward 2026 profitability.
UCB Partnership
Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
TCE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
